The IRA’s Broken Promise Is Costing Patients

A recent analysis found that nearly one in four initial attempts by patients to fill a prescription for one of the first drugs selected for Medicare’s drug price negotiation program was rejected. Patients relying on immunology and oncology treatments felt this even more intensely, with rejection rates climbing as high as 59 percent and 67 percent, respectively.